Literature DB >> 22542933

Influence of manufacturing processes on in vitro properties of the probiotic strain Lactobacillus rhamnosus Lcr35®.

Adrien Nivoliez1, Olivier Camares, Marylise Paquet-Gachinat, Stéphanie Bornes, Christiane Forestier, Philippe Veisseire.   

Abstract

Probiotics are administered as complex manufactured products and yet most studies on probiotic bacterial strains have been performed with native culture strains. Little is known about the influence of industrial processes on the properties of the microorganisms. In this study, we comparatively assessed the characteristics of the probiotic bacterial strain Lactobacillus rhamnosus (Lcr35(®)) together with four of its commercial formulations, including three intestinal formulas (BACILOR with Lcr Restituo(®) packet and capsule and FLOREA Lcr Lenio(®)) and one vaginal formula (GYNOPHILUS Lcr Regenerans(®)). Lcr35(®) grown from the intestinal formulas displayed increased resistance to acidic pH and bile stress, especially FLOREA (Lcr Lenio(®)), which showed a 4.5log higher number of viable bacteria compared to the results obtained with the control native Lcr35(®) strain. Adhesion to intestinal cells was significantly higher with Lcr Restituo(®) packet and Lcr Restituo(®) capsule vs Lcr35(®). Bacteria from the vaginal formulation GYNOPHILUS had increased ability to metabolize glycogen thereby increasing lactic acid production. In vitro growth inhibition of the pathogen Candida albicans was significantly higher with bacteria from the vaginal formulation (4.5 log difference) and in the presence of vaginal epithelial cells than with the native strain. Our results show that the manufacturing process influences strain properties and should therefore be adapted according to the strain and the therapeutic indication.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22542933     DOI: 10.1016/j.jbiotec.2012.04.005

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  9 in total

Review 1.  Insights on the Critical Parameters Affecting the Probiotic Viability During Stabilization Process and Formulation Development.

Authors:  Sharda Gurram; Durgesh K Jha; Devanshi S Shah; Madhuri M Kshirsagar; Purnima D Amin
Journal:  AAPS PharmSciTech       Date:  2021-05-18       Impact factor: 3.246

2.  Development of Probiotic Formulations for Oral Candidiasis Prevention: Gellan Gum as a Carrier To Deliver Lactobacillus paracasei 28.4.

Authors:  Felipe de Camargo Ribeiro; Juliana Campos Junqueira; Jéssica Diane Dos Santos; Patrícia Pimentel de Barros; Rodnei Dennis Rossoni; Shashank Shukla; Beth Burgwyn Fuchs; Anita Shukla; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

3.  Technological and Probiotic Traits of the Lactobacilli Isolated From Vaginal Tract of the Healthy Women for Probiotic Use.

Authors:  Hamida Bouridane; Mohamed Sifour; Tayeb Idoui; Lejeune Annick; Philip Thonard
Journal:  Iran J Biotechnol       Date:  2016-09       Impact factor: 1.671

4.  Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights.

Authors:  Cyril Poupet; Philippe Veisseire; Muriel Bonnet; Olivier Camarès; Marylise Gachinat; Caroline Dausset; Christophe Chassard; Adrien Nivoliez; Stéphanie Bornes
Journal:  Microorganisms       Date:  2019-12-23

5.  Lactobacillus rhamnosus Lcr35 as an effective treatment for preventing Candida albicans infection in the invertebrate model Caenorhabditis elegans: First mechanistic insights.

Authors:  Cyril Poupet; Taous Saraoui; Philippe Veisseire; Muriel Bonnet; Caroline Dausset; Marylise Gachinat; Olivier Camarès; Christophe Chassard; Adrien Nivoliez; Stéphanie Bornes
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

6.  Mechanistic approach to stability studies as a tool for the optimization and development of new products based on L. rhamnosus Lcr35® in compliance with current regulations.

Authors:  Claudia Muller; Virginie Busignies; Vincent Mazel; Christiane Forestier; Adrien Nivoliez; Pierre Tchoreloff
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

7.  Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.

Authors:  Jean-Marie Andrieu; Song Chen; Chunhui Lai; Weizhong Guo; Wei Lu
Journal:  Front Immunol       Date:  2014-06-30       Impact factor: 7.561

8.  Comparative phase I randomized open-label pilot clinical trial of Gynophilus® (Lcr regenerans®) immediate release capsules versus slow release muco-adhesive tablets.

Authors:  Caroline Dausset; Stéphane Patrier; Pawel Gajer; Claudia Thoral; Yann Lenglet; Jean-Michel Cardot; Philippe Judlin; Jacques Ravel; Adrien Nivoliez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-21       Impact factor: 3.267

9.  Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35.

Authors:  Caroline Dausset; Stéphanie Bornes; Sylvie Miquel; Nathalie Kondjoyan; Magaly Angenieux; Laurence Nakusi; Philippe Veisseire; Elina Alaterre; Luis G Bermúdez-Humarán; Philippe Langella; Erwan Engel; Christiane Forestier; Adrien Nivoliez
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.